Dr. Masri is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3181 SW Sam Jackson Park Rd
Portland, OR 97239Phone+1 503-494-7400Fax+1 503-494-4749
Education & Training
Cleveland Clinic FoundationResidency, Internal Medicine, 2012 - 2015
Jordan University of Science and Technology FOMClass of 2011
Certifications & Licensure
OR State Medical License 2019 - 2025
PA State Medical License 2015 - 2021
OH State Medical License 2012 - 2016- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Cardiovascular Disease
Publications & Presentations
PubMed
- The Last Decade in Cardiac Amyloidosis: Advances in Understanding Pathophysiology, Diagnosis and Quantification, Prognosis, Treatment Strategies, and Monitoring Response.Marianna Fontana, Adam Ioannou, Sarah Cuddy, Sharmila Dorbala, Ahmad Masri
JACC. Cardiovascular Imaging. 2025-01-03 - 5 citationsLong-term effect of mavacamten in obstructive hypertrophic cardiomyopathy.Pablo Garcia-Pavia, Artur Oręziak, Ahmad Masri, Roberto Barriales-Villa, Theodore P Abraham
European Heart Journal. 2024-12-16 - 1 citationsDetection of ATTR aggregates in the plasma of polyneuropathic patients with ATTR-V30M amyloidosis.Rose Pedretti, Lanie Wang, Justin L Grodin, Ahmad Masri, Jeffery Kelly
Amyloid. 2024-12-01
Lectures
- The Role of Vasculature in Valvular Heart Disease2019 ACC Scientific Session & Expo, New Orleans - 3/18/2019
- Pulmonary Hypertension In Aortic and Mitral Valve Disease: Pathophysiology and Outcomes2019 ACC Scientific Session & Expo, New Orleans - 3/18/2019
- Case Presentation2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
Press Mentions
Aortic Stenosis Outcomes Worsen with Cardiac Amyloidosis Also in the PictureJanuary 16th, 2025- OHSU Tests CRISPR Gene-Editing Technology to Treat Deadly Heart ConditionNovember 18th, 2024
- New SEQUOIA-HCM Analysis Sheds Further Light on Benefits of Aficamten in Patients with oHCMSeptember 30th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
